RGBP (Regen BioPharma) Short Interest

View and export this data going back to 2014. Start your Free Trial

What is Regen BioPharma Short Interest?

Short Interest can be expressed as a percentage by dividing the number of shares sold short by the total number of outstanding shares.

Due to the license agreement change with our data vendor, Short Interest related data is no longer available on GuruFocus website.

Competitive Comparison of Regen BioPharma's Short Interest

For the Biotechnology subindustry, Regen BioPharma's Short Interest, along with its competitors' market caps and Short Interest data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Regen BioPharma's Short Interest Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Regen BioPharma's Short Interest distribution charts can be found below:

* The bar in red indicates where Regen BioPharma's Short Interest falls into.

Regen BioPharma Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Regen BioPharma Inc (OTCPK:RGBP) » Definitions » Short Interest

Comparable Companies

Traded in Other Exchanges

RGBPP.PFD:USA

Address

4700 Spring Street, Suite 304, La Mesa, CA, USA, 91942

Website

https://www.regenbiopharmainc.com

Regen BioPharma Inc is a US-based biotechnology company. It focuses on the development of regenerative medical applications in the stem cell space. The company's principal products and services include HemaXellarate I, HemaXellerate II, dCell Vax, NR2F6, Tcellvax, identification of Small Molecules, and others. HemaXellarate I and HemaXellerate II is a cellular therapy designed to heal damaged bone marrow. dCell Vax is a therapy whereby dendritic cells of the cancer patient are harvested from the body. Tcellvax is an autologous cellular product comprised of NR2F6 gene-silenced peripheral blood mononuclear cells.